<DOC>
	<DOCNO>NCT02344550</DOCNO>
	<brief_summary>The purpose study evaluate efficacy addition everolimus letrozole LHRH agonist premenopausal metastatic breast cancer patient fail tamoxifen treatment .</brief_summary>
	<brief_title>Study GnRH-A ( Leuprorelin ) Plus Leterozole +/- Everolimus Premenopausal Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>Endocrine therapy cornerstone treatment patient hormone receptor ( HR ) -positive advanced breast cancer . The selection endocrine agent take account menopausal status , type previous adjuvant endocrine treatment , disease free interval past medical history1 . The goal endocrine treatment block interfere function estrogen progesterone . The major source estrogen premenopausal woman ovary . In premenopausal woman HR-positive advance breast cancer , tamoxifen , ovarian function suppression combination use . Unfortunately , patient response first-line endocrine therapy , even patient response eventually become resistant . Patients experience disease progression first-line endocrine therapy may benefit endocrine agent , aromatase inhibitor ( steroidal nonsteroidal ) estrogen receptor ( ER ) antagonist2-5 . Aromatase inhibitor combine luteinizing hormone-releasing hormone ( LHRH ) analogs ovarian ablation also feasible treatment modality premenopausal patient HR-positive advanced breast cancer6 . An emerge mechanism endocrine resistance aberrant signal phosphatidylinositol 3-kinase ( PI3K ) -Akt-mammalian target rapamycin ( mTOR ) signal pathway7-9 . Growing evidence support close interaction mTOR pathway ER signaling . A substrate mTOR complex 1 ( mTORC1 ) , call S6 kinase 1 , phosphorylates activation function domain 1 ER , responsible ligand-independent receptor activation10 . Everolimus sirolimus derivative inhibits mTOR allosteric binding mTORC111 . In preclinical model , use everolimus combination aromatase inhibitor result synergistic inhibition proliferation induction apoptosis12 . In randomized , phase 2 study compare neoadjuvant everolimus plus letrozole letrozole alone patient newly diagnose ER-positive breast cancer , response rate combination high letrozole alone13 . Recently , Breast Cancer Trials Oral Everolimus-2 ( BOLERO-2 ) study show addition everolimus exemestane significantly improve progression-free survival , observe median 6.9 2.8 month , correspond 57 % reduction hazard ratio14 . Based rationale , investigator introduce randomized trial evaluate efficacy addition everolimus letrozole LHRH agonist premenopausal metastatic breast cancer patient fail tamoxifen treatment .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Age â‰¥ 20 year Histologically cytologically confirm , HER2 negative breast cancer recurrent metastatic disease No HER2 overexpressing breast cancer Premenopausal status , define either ER and/or PR positive Progressive disease tamoxifen treatment sequential combine treatment tamoxifen GnRH agonist palliative adjuvant endocrine treatment Duration tamoxifen treatment least 3 month No prior treatment aromatase inhibitor inactivator fulvestrant , mTOR inhibitor One line chemotherapy metastatic setting permit ECOG performance status 0,1 2 At least one measurable lesion mainly lytic bone lesion absence measurable disease Adequate hematologic , liver kidney function Pregnant woman patient lactation More one line prior chemotherapy metastatic breast cancer GnRH agonist tamoxifen treatment within 2 week . Active malignancy breast cancer , situ carcinoma cervix , control resect thyroid well differentiate carcinoma nonmelanomatous skin cancer past 5 year Active cardiovascular disease angina , ventricular tachycardia , uncontrolled hypertension Active uncontrolled infection Symptomatic brain metastasis Lymphangitic carcinomatosis involve &gt; 50 % lung Evidence metastases involve one third liver sonogram CT Patients able unwilling give inform consent</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>metastatic breast cancer</keyword>
	<keyword>HER2 negative</keyword>
	<keyword>hormone-receptor positive</keyword>
</DOC>